Achaogen Eliminating 80 Jobs, 28% of Staff, in Restructuring

Achaogen is eliminating about 80 employees— approximately 28% of its workforce—in a restructuring designed to cut costs and refocus the antibacterial drug developer on the commercial launch of its complicated urinary tract infections (cUTI) treatment Zemdri™ (plazomicin) and two development programs.The company said it will reduce spending on early-stage R&D, technical operations and general and administrative expenses—while sparing from the proverbial axe its commerc